HLB Pharmaceutical Co. Ltd (047920) — Cash Flow Quality Index
HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow Quality Index of -0.68x as of March 2025. Operating cash flow of ₩-1.07 Billion is below net income of ₩1.57 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore HLB Pharmaceutical Co. Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
HLB Pharmaceutical Co. Ltd Cash Flow Quality Index (2014–2024)
Historical Cash Flow Quality Index for HLB Pharmaceutical Co. Ltd across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see HLB Pharmaceutical Co. Ltd (047920) cash flow conversion.
Annual Cash Flow Quality Index for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year earnings quality comparison for HLB Pharmaceutical Co. Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 3.39x | ₩6.84 Billion | ₩2.02 Billion | ▲ +18.3% |
| 2019 | 2.86x | ₩1.35 Billion | ₩472.66 Million | ▲ +875.8% |
| 2016 | -0.37x | ₩-213.11 Million | ₩577.41 Million | ▼ -107.3% |
| 2014 | 5.06x | ₩1.54 Billion | ₩304.58 Million | — |